Five-Year Summary: July 2016 to June 2021
Tables and graphs report on cancer screening and diagnostic services provided through the program in a recent 5-year period. The data represent clinical services funded directly through the NBCCEDP as reported in the April 2022 submission of the NBCCEDP Minimum Data Elements (MDE).
National aggregate data are typically used to report results from the program and as a standard to compare results of grantee programs. Comparing data across grantee programs is not advised due to extensive variation across programs. For information on interpreting the data, refer to Screening Program Data. For information on the program, refer to About the Program.
Data for the following are suppressed for programs with fewer than 200 screens, cell sizes less than 16, and rates and percentages that do not meet a test of relative standard error less than 30%, a measure of the estimate’s reliability. Differences are due to rounding.
|Women served ||35,023|
|Women receiving cervical cancer screening and diagnostic services||26,028|
|Women receiving breast cancer screening and diagnostic services||21,197|
Each category reports counts of unduplicated women receiving services within the 5-year period. Women may be counted in more than one category.
1: Women served includes women receiving any screening or diagnostic procedure with services funded through the NBCCEDP.
Data source: April 2022 submission of NBCCEDP Minimum Data Elements (MDE) for New Jersey.
Cervical Cancer Services
This pie chart illustrates the distribution of 26,028 women receiving NBCCEDP-funded cervical services from July 2016 to June 2021 by race and ethnicity.
*Slices too small to view were combined into the Other Races slice (1.2%) and include: American Indian/Alaska Native (0.1%), Multiracial (0.1%), and Unknown (0.9%). Differences are due to rounding.
This pie chart illustrates the distribution of 26,028 women receiving NBCCEDP-funded cervical services from July 2016 to June 2021 by age.
|HPV tests provided||16,751|
|HPV tests with abnormal results ||2,312|
|Percentage of HPV tests with abnormal results||13.8|
|Pap tests provided||29,906|
|Pap tests with abnormal results ||1,039|
|Percentage of Pap tests with abnormal results||3.5|
|Age-adjusted percentage ||2.9|
|Cervical cancers or premalignant cervical lesions ||741|
|CIN1 or LSIL||568|
|CIN2 or worse ||173|
|Rate of CIN2 or worse detected per 1,000 Pap tests ||5.8|
|Age-adjusted rate per 1,000 Pap tests ||4.5|
1: Abnormal HPV test results include: all positive high-risk HPV test results.
2: Abnormal Pap test results include: low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), atypical squamous cells of undetermined significance – cannot exclude HSIL (ASC-H), atypical glandular cells (AGC), and squamous cell cancer.
3: Adjusted to the age distribution of NBCCEDP participants having Pap tests performed in calendar year 2000.
4: Includes LSIL, HSIL, cervical intraepithelial neoplasia (CIN)1, CIN2, CIN3, carcinoma in situ (CIS), and invasive cervical cancer.
5: Includes HSIL, CIN2, CIN3, CIS, and invasive cervical cancer.
Table includes HPV and Pap tests provided to women with services funded through the NBCCEDP.
Breast Cancer Services
This pie chart illustrates the distribution of 21,197 women receiving NBCCEDP-funded breast services from July 2016 to June 2021 by race and ethnicity.
*Slices too small to view were combined into the Other Races slice (0.2%) and include: American Indian/Alaska Native (0.1%) and Multiracial (0.2%). Differences are due to rounding.
This pie chart illustrates the distribution of 21,197 women receiving NBCCEDP-funded breast services from July 2016 to June 2021 by age.
|Mammograms with abnormal results ||5,075|
|Percentage of mammograms with abnormal results||21.5|
|Age-adjusted percentage ||21.1|
|Breast cancers detected ||201|
|Rate of breast cancers detected per 1,000 mammograms||8.5|
|Age-adjusted rate per 1,000 mammograms ||9.4|
1: Abnormals include mammogram results of: suspicious abnormality, highly suggestive of malignancy, and assessment incomplete (further imaging studies or film comparisons required).
2: Adjusted to the age distribution of NBCCEDP participants 40 years of age and older having mammograms performed in calendar year 2000.
3: Breast cancers include invasive breast cancer, ductal carcinoma in situ (DCIS), and other in situ excluding lobular carcinoma in situ (LCIS).
Table includes mammograms provided to women age 40 and older with services funded through the NBCCEDP.